Advertisement
Advertisement

BCLI

BCLI logo

Brainstorm Cell Therapeutics, Inc.

2.20
USD
+0.41
+22.91%
Dec 18, 15:59 UTC -5
Closed
...

Brainstorm Cell Therapeutics, Inc. Profile

About

BrainStorm Cell Therapeutics Inc. is a biotechnology company. It develops autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Multiple Sclerosis and Parkinson's disease. Brainstorm Cell Therapeutics is based in New York.

Info & Links

CEO

Chaim Lebovits

Headquarters

1325 AVENUE OF AMERICAS, 28TH FLOOR
NEW YORK, NY 10019, UNITED STATES

Auditor

Brightman Almagor Zohar & Co.

Share holders

30

Employees

29

Brainstorm Cell Therapeutics, Inc. Statistics

Valuation Measures

Market Capitalization2

12.54M

Enterprise Value

12.37M

Enterprise Value/EBITDA(ttm)

-0.95

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

--

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

--

Return on Invested Capital(ttm)

292.85%

Return on Assets(ttm)

-528.56%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-13.05M

Net Income Available to Common(ttm)

-14.23M

Diluted EPS(ttm)

-4.80

Share Statistics

Beta (5Y Monthly)

0.36

52-Week Change

-63.33%

S&P 500 52-Week Change

23.87%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

5.70M

Dividend Yield

0.00%

Float4

5.32M

% Held by Insiders

6.70%

% Held by Institutions

14.33%

Balance Sheet

Total Cash(mrq)

168.00K

Total Cash Per Share(mrq)

0.03

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

0.05%

Quick Ratio(mrq)

0.05%

Book Value Per Share(mrq)

-1.14

Cash Flow

Operating Cash Flow Per Share(ytd)

-1.52

Free Cash Flow(ytd)

-8.04M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement